Our Mission

To be a leader as a successful independent pharmaceutical company through:

  • Research & Development,
  • Quality,
  • Manufacturing,
  • Sales, and
  • Customer Service.

ES Pharma is dedicated to delivering high-quality, branded and generic medications trusted by healthcare professionals and patients across geographies. We are an emerging specialty pharmaceutical company with a focus on research, process chemistry, active pharmaceutical ingredient procurement, formulation development and regulatory filings. ES Pharma is committed to achieving its mission and vision of becoming an innovative pharmaceutical company.

Recent FDA News

FDA approves Inlyta to treat patients with a type of advanced kidney cancer

January 27, 2012
The U.S. Food and Drug Administration today approved Inlyta (axitinib) to treat patients with advanced kidney cancer (renal cell carcinoma) who have not responded to another drug for this type of cancer.

Department of Justice files Consent Decree of Permanent injunction against Ranbaxy

January 25, 2012
Generic drug manufacturer agrees to remedy deviations from the current good manufacturing practice requirements and to correct data integrity problems at numerous facilities

Maine company holds cold smoked salmon product after FDA order

January 24, 2012
A Maine food processing and storage company destroyed its cold smoked salmon product under the supervision of the U.S. Food and Drug Administration after inspectors found Listeria monocytogenes within the firm's facility and on processing equipment

FDA permits marketing of first test for risk of rare brain infection in some people treated with Tysabri

January 20, 2012
Today, the U.S. Food and Drug Administration allowed marketing of the first test to help determine the risk for a rare brain infection called progressive multifocal leukoencephalopathy (PML) in people using the drug Tysabri (natalizumab) to treat multiple sclerosis (MS) or Crohn's disease (CD).

FDA approves Voraxaze to treat patients with toxic methotrexate levels

January 17, 2012
The U.S. Food and Drug Administration today approved Voraxaze (glucarpidase) to treat patients with toxic levels of methotrexate in their blood due to kidney failure. Methotrexate is a commonly used cancer chemotherapy drug normally eliminated from the body by the kidneys. However, patients receiving high doses of methotrexate may develop kidney failure.